Results 11 to 20 of about 978,474 (275)

THE PRESCRIBING TRENDS OF ACE-INHIBITORS AFTER MYOCARDIAL INFARCTION IN TERTIARY CARE HOSPITALS OF HAZARA REGION

open access: yesInternational Journal of Pharmacy & Integrated Health Sciences
Background: There is good evidence that angiotensin-converting enzyme (ACE) inhibitors are beneficial after myocardial infarction (MI). However, it is not known how widely this evidence is used in practice or whether all eligible patients receive this ...
Fiaz Alam   +6 more
doaj   +2 more sources

EVIDENCE-BASED CHOICE OF ACE INHIBITORS

open access: yesРоссийский кардиологический журнал, 2012
Angiotensin-converting enzyme (ACE) inhibitors are currently one of the most frequently used groups of cardiovascular medications. In addition to wellknown indications, such as arterial hypertension (AH), chronic heart failure (CHF), and Type 2 diabetes ...
G. E. Gendlin   +2 more
doaj   +1 more source

ACE inhibitors as a risk factor for hypoglycemia [PDF]

open access: yesСахарный диабет, 2011
It is known that hypoglycemia is associated with an increased risk of cardiovascular adverse events including death. ACE-inhibitors, when taken withantidiabetic drugs, can cause hypoglycemic episodes by improving insulin sensitivity.
Andrey Alexeevich Aleksandrov   +7 more
doaj   +2 more sources

Impact of angiotensin converting enzyme inhibition on post- coronary artery bypass interleukin 6 release [PDF]

open access: yes, 2002
Background: Angiotensin 1 converting enzyme (ACE) inhibitors reduce morbidity and mortality after coronary artery bypass graft surgery (CABG). This benefit may result from an anti- inflammatory action.
Humphries, S.E.   +5 more
core   +6 more sources

Incidence of adverse events with telmisartan compared with ACE inhibitors: evidence from a pooled analysis of clinical trials [PDF]

open access: yesPatient Preference and Adherence, 2011
Giuseppe Mancia1, Helmut Schumacher21Universita degli Studi Milano-Bicocca, Ospedale San Gerardo di Monza, Milan, Italy; 2Boehringer Ingelheim Pharma GmbH and Co KG, Ingelheim, GermanyAbstract: Telmisartan is indicated for the prevention of ...
Mancia G, Schumacher H
doaj   +1 more source

The angiotensin-converting enzyme (ACE) gene family of Anopheles gambiae [PDF]

open access: yes, 2005
Background Members of the M2 family of peptidases, related to mammalian angiotensin converting enzyme (ACE), play important roles in regulating a number of physiological processes.
Lee, A.J.   +19 more
core   +6 more sources

Pharmacology of modern ACE inhibitors: moexipril example [PDF]

open access: yesКардиоваскулярная терапия и профилактика, 2007
ACE inhibitors are widely used in the treatment of arterial hypertension, chronic heart failure, and other cardiovascular pathology. The article is devoted to ACE pharmacology and their optimal use in clinical practice.
D. P. Khloponin   +2 more
doaj   +1 more source

SIGNIFICANCE OF BASELINE ACE ACTIVITY IN PATIENTS WITH METABOLIC SYNDROME WHEN ADMINISTRATION OF ACE INHIBITORS AND IMIDAZOLINE AGONISTS IS CONSIDERED

open access: yesРоссийский кардиологический журнал, 2001
Significance of baseline ACE activity in patients with metabolic syndrome when administration of ACE inhibitors and imidazoline agonists is considered.
T. V. Aparina   +4 more
doaj   +1 more source

Angiotensin-converting enzyme (ACE) inhibitor prescription affects non-small-cell lung cancer (NSCLC) patients response to PD-1/PD-L1 immune checkpoint blockers

open access: yesOncoImmunology, 2020
Angiotensin-converting enzyme (ACE) inhibitors are frequently used to treat hypertension and congestive heart failure. Preclinical data show that ACE plays a role on both innate and adaptive immune responses. Since interactions between ACE inhibitors and
Soleine Medjebar   +9 more
doaj   +1 more source

Effects of adding tripterygium glycosides to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on albuminuria in patients with diabetic nephropathy

open access: yesChronic Diseases and Translational Medicine, 2020
Introduction: Tripterygium glycosides (TGs) have been widely used in China to treat diabetic nephropathy (DN); however, proof of their use is scarce. The present study aimed to evaluate the effectiveness and safety of adding TGs to angiotensin-converting
Jin-Ying Fang   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy